DK1701944T3 - 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme - Google Patents

2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme

Info

Publication number
DK1701944T3
DK1701944T3 DK05726205T DK05726205T DK1701944T3 DK 1701944 T3 DK1701944 T3 DK 1701944T3 DK 05726205 T DK05726205 T DK 05726205T DK 05726205 T DK05726205 T DK 05726205T DK 1701944 T3 DK1701944 T3 DK 1701944T3
Authority
DK
Denmark
Prior art keywords
pyramidines
aryl
amino
substituted
treatment
Prior art date
Application number
DK05726205T
Other languages
Danish (da)
English (en)
Inventor
Paul E Fleming
Zhan Shi
Shaowu Chen
Jane F Schmidt
John C Reader
Neal D Hone
Jefrey P Ciavarri
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34749013&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1701944(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of DK1701944T3 publication Critical patent/DK1701944T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
DK05726205T 2004-01-08 2005-01-10 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme DK1701944T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53489804P 2004-01-08 2004-01-08
PCT/US2005/000663 WO2005066139A2 (en) 2004-01-08 2005-01-10 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
DK1701944T3 true DK1701944T3 (da) 2009-11-09

Family

ID=34749013

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05726205T DK1701944T3 (da) 2004-01-08 2005-01-10 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme

Country Status (18)

Country Link
US (2) US7732444B2 (es)
EP (2) EP2123647A1 (es)
JP (1) JP2007517895A (es)
AR (1) AR047185A1 (es)
AT (1) ATE437861T1 (es)
AU (1) AU2005204060A1 (es)
CA (1) CA2559888A1 (es)
CY (1) CY1109529T1 (es)
DE (1) DE602005015677D1 (es)
DK (1) DK1701944T3 (es)
ES (1) ES2330863T3 (es)
HR (1) HRP20090572T1 (es)
PL (1) PL1701944T3 (es)
PT (1) PT1701944E (es)
RS (1) RS51091B (es)
SI (1) SI1701944T1 (es)
TW (1) TW200533357A (es)
WO (1) WO2005066139A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
BRPI0508230A (pt) * 2004-03-30 2007-07-17 Chiron Corp derivados de tiofeno substituìdo como agentes anti-cáncer
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
JP2009521488A (ja) * 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
EP2001868B1 (en) * 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
LT2430921T (lt) * 2007-04-03 2017-09-25 E. I. Du Pont De Nemours And Company Pakeistieji benzeno fungicidai
RS53850B2 (sr) † 2007-10-30 2018-07-31 Genentech Inc Pročišćavanje antitela hromatografijom izmene katjona
CA2716898A1 (en) 2008-02-27 2009-09-03 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
EP2169665B1 (en) 2008-09-25 2018-05-02 LG Electronics Inc. A method and an apparatus for processing a signal
WO2011083482A2 (en) * 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of psoriasis
US20130109019A1 (en) * 2010-07-02 2013-05-02 Adrian E. Murillo Hapten conjugates for target detection
EP2681215B1 (en) 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
EP2739618B1 (en) 2011-08-04 2015-09-16 Array Biopharma, Inc. Quinazoline compounds as serine/threonine kinase inhibitors
UA116774C2 (uk) 2012-03-01 2018-05-10 Еррей Біофарма Інк. Інгібітори серин/треонінкінази
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
CN107200749B (zh) 2013-03-12 2019-09-03 沃泰克斯药物股份有限公司 Dna-pk抑制剂
US10124001B2 (en) 2013-09-18 2018-11-13 University Of Canberra Stem cell modulation II
EP3057953B1 (en) 2013-10-17 2018-08-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
WO2023104744A1 (en) 2021-12-06 2023-06-15 Helmholtz-Zentrum Dresden-Rossendorf E.V. 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698697A (en) 1995-07-19 1997-12-16 Mitsubishi Chemical Corporation 2-cyanopiperazine and method of producing the same
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
CA2321153A1 (en) * 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
DE69919707T2 (de) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1140901A2 (en) 1998-12-24 2001-10-10 Aventis Pharmaceuticals Products Inc. Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
MY133159A (en) 1999-08-13 2007-10-31 Vertex Pharma Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
CZ20031028A3 (cs) 2000-10-12 2003-08-13 Merck & Co., Inc. Aza- a polyazanaftalenylkarboxamidy
CA2441733A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
DE60214701T2 (de) * 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
GB0112803D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
RU2308455C2 (ru) 2001-11-07 2007-10-20 Ф.Хоффманн-Ля Рош Аг Аминопиримидины и пиридины
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
CA2489458A1 (en) * 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
CA2514612A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
EP1611123B8 (en) 2003-04-09 2013-11-13 Exelixis, Inc. Tie-2 modulators and methods of use
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
BRPI0508230A (pt) * 2004-03-30 2007-07-17 Chiron Corp derivados de tiofeno substituìdo como agentes anti-cáncer
AU2005245386B2 (en) 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
TW200610762A (en) 2004-06-10 2006-04-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1809290A2 (en) * 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
CN101115749B (zh) 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DE102005034821A1 (de) * 2005-07-26 2007-02-08 Fleissner Gmbh Voluminöse Faserlaminate und ihre Herstellung
TWM293131U (en) * 2006-01-10 2006-07-01 Shuen Tai Prec Entpr Co Ltd Handheld power hammer

Also Published As

Publication number Publication date
JP2007517895A (ja) 2007-07-05
RS51091B (sr) 2010-10-31
TW200533357A (en) 2005-10-16
DE602005015677D1 (de) 2009-09-10
CA2559888A1 (en) 2005-07-21
ATE437861T1 (de) 2009-08-15
AU2005204060A1 (en) 2005-07-21
PL1701944T3 (pl) 2010-01-29
EP1701944B1 (en) 2009-07-29
US20110071134A1 (en) 2011-03-24
ES2330863T3 (es) 2009-12-16
PT1701944E (pt) 2009-11-03
US20060040968A1 (en) 2006-02-23
WO2005066139A3 (en) 2005-10-13
SI1701944T1 (sl) 2010-03-31
AR047185A1 (es) 2006-01-11
US8268822B2 (en) 2012-09-18
EP2123647A1 (en) 2009-11-25
CY1109529T1 (el) 2014-08-13
US7732444B2 (en) 2010-06-08
HRP20090572T1 (hr) 2010-01-31
EP1701944A2 (en) 2006-09-20
WO2005066139A2 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
DK1701944T3 (da) 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK2463283T3 (da) Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1849773T3 (da) Piperazinderivater til behandlingen af urininkontinens og smerte
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2878297T3 (da) Lægemidler til behandling og forebyggelse af fibrotiske sygdomme
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater